SPX 101

Drug Profile

SPX 101

Alternative Names: SPX-101

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spyryx Biosciences
  • Class Antifibrotics; Peptides
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis
  • Preclinical Lung disorders

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Lung disorders in USA (Inhalation)
  • 01 Nov 2017 Pharmacodynamics data from a preclinical trial in Cystic fibrosis released by Spyryx Biosciences
  • 02 Aug 2017 Spyryx Biosciences completes a phase Ib trial in Cystic fibrosis in Canada (Inhalation) (NCT03056989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top